Title : AKT activation predicts outcome in breast cancer patients treated with tamoxifen.

Pub. Date : 2005 Oct

PMID : 16088978






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AKT activation predicts outcome in breast cancer patients treated with tamoxifen. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens
2 The present study was carried out to test the hypothesis that AKT activation mediates tamoxifen resistance in clinical breast cancer. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens
3 The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens
4 The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens
5 The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens
6 The data presented here show that the PI3K/AKT/mTOR pathway is associated with relapse and death in ERalpha-positive breast cancer patients treated with tamoxifen, supporting in vitro evidence that AKT mediates tamoxifen resistance. Tamoxifen AKT serine/threonine kinase 1 Homo sapiens